The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The United States Food and Drug Administration selected the supplemental Biologics License Application for teclistamab (TECVAYLI) plus daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) to
LOS ANGELES—SOHO Insider, the official media platform of the Society of Hematologic Oncology (SOHO) has announced the launch of its Virtual Community Oncology
The FDA has granted priority review nivolumab in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric patients who are 12
Dr. Nina Shah leads a discussion at 2:00 pm CST on November 10, 2026, on how can pharma engage with community oncologists.
Dr. Shakira Grant leads a discussion at 1:00 pm CST on October 13, 2026, on AI impacting pathology and treatment decisions.
Dr. Hans Lee leads a discussion at 12:30 pm CST on September 2, 2026, on increasing US representation in global clinical trials.
Dr. Marin Xavier leads a discussion at 3:00 pm CST on August 11, 2026, on integrating new evidence into everyday practice.
Dr. Gwen Nichols leads a discussion at 12:15 pm CST on July 13, 2026, on addressing funding gaps in blood cancer research.
SOHO Asia 2026 will focus on the latest advances in leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms (MPNs), featuring leading experts from across
The US Food and Drug Administration accepted and granted priority review to a new drug application for sonrotoclax, a next-generation BCL2 inhibitor, for
